Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > You guys do realize...

<< Previous

Bullboard Posts

Next >>

Comment by TheTerminator1on Jul 16, 2021 11:37am

80 Views

Post# 33559632

RE:RE:RE:You guys do realize...

I like your post,it's more than realistic!

90guppy wrote:

captainbrouwer wrote: Sotrovimab given EUA for covid recently at 583 patients. 291 received sotrovimab, 292 placebo.

Bucillamine trial until now has been 1:1:1 300g:600g:placebo. So 66% have had bucillamine, i.e. 266 patients. Pretty damn close to 291. Only half of them had the 600g dose they've selected to continue for rest of study, but that 300g data is surely still valuable. The question is how valuable. I don't know.

Rest of the study will be 2:1 bucillamine: placebo.

Refs: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19

https://clinicaltrials.gov/ct2/show/NCT04545060

https://clinicaltrials.gov/ct2/show/NCT04504734

Right on! and watch out for licensing deals before that, that could be massive catalyst too, while waiting for EUA

Example of big licensing deals